###begin article-title 0
###xml 38 43 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Recruitment and Activation of RSK2 by HIV-1 Tat
###end article-title 0
###begin p 1
Conceived and designed the experiments: MO DB CH. Performed the experiments: AP DB CH KB AS KK KK. Analyzed the data: MO AP DB CH KB AS KK KK. Contributed reagents/materials/analysis tools: JT MC. Wrote the paper: MO CH.
###end p 1
###begin p 2
Current address: Salk Institute for Biological Studies, La Jolla, California, United States of America
###end p 2
###begin p 3
###xml 47 50 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 918 921 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1092 1095 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The transcriptional activity of the integrated HIV provirus is dependent on the chromatin organization of the viral promoter and the transactivator Tat. Tat recruits the cellular pTEFb complex and interacts with several chromatin-modifying enzymes, including the histone acetyltransferases p300 and PCAF. Here, we examined the interaction of Tat with activation-dependent histone kinases, including the p90 ribosomal S6 kinase 2 (RSK2). Dominant-negative RSK2 and treatment with a small-molecule inhibitor of RSK2 kinase activity inhibited the transcriptional activity of Tat, indicating that RSK2 is important for Tat function. Reconstitution of RSK2 in cells from subjects with a genetic defect in RSK2 expression (Coffin-Lowry syndrome) enhanced Tat transactivation. Tat interacted with RSK2 and activated RSK2 kinase activity in cells. Both properties were lost in a mutant Tat protein (F38A) that is deficient in HIV transactivation. Our data identify a novel reciprocal regulation of Tat and RSK2 function, which might serve to induce early changes in the chromatin organization of the HIV LTR.
###end p 3
###begin title 4
Introduction
###end title 4
###begin p 5
###xml 147 150 147 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Kao1">[1]</xref>
###xml 302 305 302 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 414 417 414 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Peterlin1">[2]</xref>
###xml 715 718 715 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Jordan1">[3]</xref>
###xml 914 917 914 917 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Cullen1">[4]</xref>
###xml 1110 1113 1110 1113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Wei1">[5]</xref>
###xml 1322 1325 1322 1325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Herrmann1">[6]</xref>
###xml 1327 1330 1327 1330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Zhu1">[7]</xref>
###xml 19 22 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 629 632 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 885 888 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The early phase of HIV transcription is characterized by the absence of the viral transactivator Tat and a block in viral transcription elongation [1]. During this phase, basal activity of the viral promoter is controlled by the local chromatin environment, cellular transcription factors that bind to cis-acting elements in the viral promoter, and the processivity of the recruited RNA polymerase II (reviewed in [2]). Although inefficient, basal promoter activity is thought to result in a few full-length viral transcripts and synthesis of Tat. Tat dramatically increases the production of full-length transcripts and renders HIV transcription independent of the chromatin environment at the site of integration [3]. Among its functions, Tat recruits the positive transcription elongation factor b (pTEFb) to the TAR element, an RNA stem loop structure at the 5' termini of nascent HIV transcripts (reviewed in [4]). The arginine-rich motif in Tat (amino acids 49-57) binds to a bulge structure in TAR, while the Tat transactivation domain (amino acids 1-48) associates with the cyclinT1 component in pTEFb [5]. CyclinT1 exists as a complex with cyclin-dependent kinase 9 (CDK9), which hyperphosphorylates the C-terminal domain of RNA polymerase II, increasing its ability to elongate efficiently on the viral template [6], [7].
###end p 5
###begin p 6
###xml 84 87 84 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Strahl1">[8]</xref>
###xml 166 169 166 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Orphanides1">[9]</xref>
###xml 171 175 171 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Hampsey1">[10]</xref>
###xml 274 278 274 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-VanLint1">[11]</xref>
###xml 280 284 280 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Hsia1">[12]</xref>
###xml 286 290 286 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-He1">[13]</xref>
###xml 292 296 292 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Lusic1">[14]</xref>
###xml 298 302 298 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Zhou1">[15]</xref>
###xml 473 477 473 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Kamine1">[16]</xref>
###xml 479 483 479 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Benkirane1">[17]</xref>
###xml 485 489 485 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Hottiger1">[18]</xref>
###xml 491 495 491 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Marzio1">[19]</xref>
###xml 497 501 497 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Weissman1">[20]</xref>
###xml 503 507 503 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Col1">[21]</xref>
###xml 509 513 509 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Mujtaba1">[22]</xref>
###xml 515 519 515 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Dorr1">[23]</xref>
###xml 579 583 579 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Col1">[21]</xref>
###xml 585 589 585 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Kiernan1">[24]</xref>
###xml 591 595 591 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Ott1">[25]</xref>
###xml 597 601 597 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Deng1">[26]</xref>
###xml 261 264 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 462 467 <span type="species:ncbi:9606">human</span>
###xml 568 573 <span type="species:ncbi:9606">human</span>
Various histones modifications occur during transcriptional activation (reviewed in [8]), and some are specifically linked to transcriptional elongation (reviewed in [9], [10]). Histone acetylation and methylation correlate with transcriptional activity of the HIV promoter [11], [12], [13], [14], [15]. Tat interacts with several transcriptional cofactors that have intrinsic histone acetyltransferase (HAT) activity, including Tip60, p300/CBP, PCAF, TAFII250, human GCN5 [16], [17], [18], [19], [20], [21], [22], [23], and is itself acetylated by p300/CBP, PCAF and human GCN5 [21], [24], [25], [26].
###end p 6
###begin p 7
###xml 274 278 274 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Mahadevan1">[27]</xref>
###xml 415 419 415 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Lo1">[28]</xref>
###xml 421 425 421 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Cheung1">[29]</xref>
###xml 514 518 514 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Thomson1">[30]</xref>
###xml 520 524 520 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Soloaga1">[31]</xref>
###xml 743 747 735 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-SassoneCorsi1">[32]</xref>
###xml 749 753 741 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Thomson2">[33]</xref>
###xml 755 759 747 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Anest1">[34]</xref>
###xml 761 765 753 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Yamamoto1">[35]</xref>
Histones can also be phosphorylated in response to several cellular processes. In particular, the rapid and transient mitogen-induced phosphorylation of serine 10 in the tail of histone H3 has been coupled to the transcriptional activation of immediate-early response genes [27]. This phosphorylation event is an early marker in mitogen-induced gene activation and can control subsequent histone acetylation events [28], [29]. However, for some genes histone phosphorylation and acetylation are independent events [30], [31]. Activation-dependent mammalian kinases with intrinsic histone H3 kinase activity include ribosomal S6 protein kinase 2 (RSK2), mitogen- and stress-activated protein kinase 1 (MSK1) and IkappaB kinase alpha (IKKalpha) [32], [33], [34], [35].
###end p 7
###begin p 8
###xml 269 273 269 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Fisher1">[36]</xref>
###xml 524 528 524 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Frdin1">[37]</xref>
###xml 726 730 726 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Young1">[38]</xref>
###xml 732 736 732 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Trivier1">[39]</xref>
###xml 738 742 738 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Jacquot1">[40]</xref>
###xml 744 748 744 748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Hanauer1">[41]</xref>
###xml 962 966 962 966 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-SassoneCorsi1">[32]</xref>
###xml 1087 1091 1087 1091 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Soloaga1">[31]</xref>
###xml 1093 1097 1093 1097 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Davie1">[42]</xref>
###xml 1210 1214 1210 1214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Merienne1">[43]</xref>
###xml 1216 1220 1216 1220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Nakajima1">[44]</xref>
###xml 1222 1226 1222 1226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Xing1">[45]</xref>
###xml 1228 1232 1228 1232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Swanson1">[46]</xref>
###xml 1374 1378 1374 1378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Yang1">[47]</xref>
###xml 771 779 <span type="species:ncbi:9606">patients</span>
###xml 1365 1373 <span type="species:ncbi:9606">patients</span>
RSK2 is one of four RSK serine-threonine kinases that are activated through the mitogen-activated protein kinase (MAPK) signal transduction pathway. RSK family members are unusual because they contain two distinct kinase domains that are both catalytically functional. [36] The N-terminal kinase domain phosphorylates downstream targets and is activated through a sequential phosphorylation cascade involving 3-phosphoinositide-dependent protein kinase 1 (PDK1), the C-terminal kinase domain of RSK2 and ERK1/2 (reviewed in [37]). Inactivating mutations and truncations in the RSK2 gene are responsible for Coffin-Lowry syndrome (CLS), which is characterized by severe mental retardation and progressive skeletal deformations [38], [39], [40], [41]. Fibroblasts from CLS patients were found deficient in histone phosphorylation induced by treatment with epidermal growth factor (EGF), indicating that RSK2 is relevant for mitogen-induced histone phosphorylation [32]. However, more recent results show a prominent role of MSK1/2 in mitogen- and stress-induced histone H3 phosphorylation [31], [42]. RSK2 also phosphorylates transcriptional coactivators and transcription factors, including CBP, CREB and c-fos [43], [44], [45], [46]. The transcription factor ATF4 was identified as a preferred substrate for RSK2 and was linked to the skeletal abnormalities in CLS patients [47].
###end p 8
###begin p 9
###xml 165 168 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
In this study, we examined the role of histone kinases in Tat transactivation. We have observed that Tat increases phosphorylation of histone H3 associated with the HIV promoter. Our findings identify a novel role of Tat as an adaptor and activator of RSK2 in cells and show that RSK2 activity is required for full transactivation of Tat.
###end p 9
###begin title 10
Results
###end title 10
###begin title 11
###xml 39 42 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Histone H3 hyperphosphorylation at the HIV LTR in the presence of Tat
###end title 11
###begin p 12
###xml 184 193 184 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000151-g001">Figure 1A</xref>
###xml 377 380 377 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Jordan1">[3]</xref>
###xml 43 46 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 258 261 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 466 469 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 529 532 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 669 672 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 891 894 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
To study histone H3 phosphorylation of the HIV promoter, we performed chromatin immunoprecipitation (ChIP) studies with antibodies specific for phosphorylated serine 10 in histone H3 (Figure 1A). We used extracts from Jurkat T cells containing an integrated HIV promoter which were either infected with a lentiviral vector expressing the green fluorescent protein (GFP) or Tat [3]. Immunoprecipitations were followed by radioactive PCR with primers specific for the HIV LTR, the c-fos, or the beta-globin genes. We observed that HIV LTR-specific sequences were enriched in immunoprecipitates from Tat-expressing cells, indicating that histone H3 phosphorylation at the HIV promoter was increased in the presence of Tat. No difference between GFP- and Tat-expressing cells was detected for the c-fos or beta-globin genes, demonstrating that the observed increase was specific for Tat and the HIV promoter.
###end p 12
###begin title 13
Kinase-deficient RSK2 suppresses Tat transactivation
###end title 13
###begin p 14
###xml 409 418 401 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000151-g001">Figure 1B</xref>
###xml 684 693 676 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000151-g001">Figure 1C</xref>
###xml 867 876 859 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000151-g001">Figure 1D</xref>
###xml 1096 1105 1088 1097 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000151-g001">Figure 1E</xref>
###xml 226 229 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 395 398 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 783 786 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
To examine the influence of histone kinases on Tat transactivation, kinase-deficient RSK2, MSK1 or IKKalpha with known dominant-negative properties were transiently overexpressed in Jurkat 1G5 T cells containing an integrated HIV promoter luciferase construct. Coexpression of kinase-deficient RSK2, but not of kinase-deficient MSK1 or IKKalpha, inhibited the activity of coexpressed Tat on the HIV promoter (Figure 1B). Basal LTR activity was unaffected when kinase-deficient RSK2 was transfected in the absence of Tat, indicating that the effect of RSK2 is specific for Tat. Expression of kinase-deficient RSK2 had no effect on Tat expression as confirmed by western blot analysis (Figure 1C). Accordingly, kinase-deficient RSK2 did not affect the activity of the cytomegalovirus (CMV) immediate-early promoter that was driving Tat expression in these experiments (Figure 1D). In addition, no effect was observed on the activity of a Gal4-CDK9 fusion protein that transactivates the 5xUAS promoter, excluding the possibility that RSK2 regulates the activity of the Tat-associated kinase pTEFb (Figure 1E).
###end p 14
###begin title 15
RSK2 expression is required for Tat transactivation
###end title 15
###begin p 16
###xml 144 153 144 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000151-g002">Figure 2A</xref>
###xml 459 468 459 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000151-g002">Figure 2B</xref>
###xml 589 599 589 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000151-g002">Figures 2B</xref>
###xml 871 880 871 880 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000151-g002">Figure 2C</xref>
###xml 71 78 <span type="species:ncbi:9606">patient</span>
###xml 220 223 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 445 448 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Next, we examined Tat transactivation in a fibroblast cell line from a patient with CLS. No RSK2 protein was detected by western blot analysis (Figure 2A). We used nuclear microinjections to introduce synthetic Tat, the HIV LTR luciferase reporter, and a GFP expression plasmid into these cells. Coinjection of an RSK2-expressing plasmid increased Tat transactivation levels fivefold, demonstrating that RSK2 synergizes with Tat to activate the HIV promoter (Figure 2B). Kinase-deficient RSK2 had no effect, indicating that the catalytic activity of RSK2 is required for synergy with Tat (Figures 2B). No dominant-negative effect of kinase-deficient RSK2 was observed due to the lack of endogenous RSK2 in CLS cells. RSK2 did not affect the 5xUAS promoter activated by the Gal4-VP16 transactivator, indicating that the effect of RSK2 is specific for Tat transactivation (Figure 2C).
###end p 16
###begin title 17
Binding of RSK2 to the transactivation domain in Tat
###end title 17
###begin p 18
###xml 84 88 84 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Hauber1">[48]</xref>
###xml 90 94 90 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Chen1">[49]</xref>
###xml 440 449 436 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000151-g003">Figure 3A</xref>
###xml 696 705 692 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000151-g003">Figure 3B</xref>
###xml 845 854 841 850 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000151-g003">Figure 3C</xref>
###xml 955 964 951 960 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000151-g003">Figure 3B</xref>
###xml 997 1006 993 1002 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000151-g003">Figure 3C</xref>
###xml 746 749 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 836 839 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Tat is a nuclear protein, while RSK2 shuttles between the cytoplasm and the nucleus [48], [49]. To determine if the two proteins interact physically in cells, we transfected Cos7 cells with RSK2/HA and Tat/FLAG, and immunoprecipitated the nuclear extracts with alpha-FLAG agarose. RSK2 coimmunoprecipitated with Tat in cells transfected with RSK2 and Tat expression vectors, but no signal was obtained when RSK2 or Tat was expressed alone (Figure 3A). The same was observed when RSK2 was immunoprecipitated with HA-specific antibodies and recovery of Tat was analyzed (data not shown). Tat also coimmunoprecipitated with endogenous RSK2 in Tat-expressing, but not vector-transfected, Cos7 cells (Figure 3B) and in Jurkat T cells infected with an HIV-based lentiviral vector, where Tat expression was driven by its natural promoter, the HIV LTR (Figure 3C). No RSK2- or Tat-specific signals were obtained after immunoprecipitation with a control antibody (Figure 3B) or with sepharose beads alone (Figure 3C).
###end p 18
###begin p 19
###xml 343 360 343 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000151-g003">Figure 3D, lane 1</xref>
###xml 457 474 457 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000151-g003">Figure 3D, lane 8</xref>
###xml 644 661 644 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000151-g003">Figure 3D, lane 2</xref>
###xml 777 794 777 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000151-g003">Figure 3D, lane 3</xref>
###xml 945 962 945 962 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000151-g003">Figure 3D, lane 4</xref>
###xml 1077 1081 1077 1081 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Jones1">[50]</xref>
###xml 1264 1288 1264 1288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000151-g003">Figure 3D, lanes 5, 6, 7</xref>
###xml 170 175 <span type="species:ncbi:9606">human</span>
To further examine the Tat/RSK2 interaction, recombinant Tat (amino acids 1-86) fused to the C-terminus of glutathione-S-transferase (GST) was incubated with full-length human RSK2 isolated from insect cells. After pulldown with glutathione-sepharose, RSK2 copelleted with GST-Tat 1-86, demonstrating direct interaction between both proteins (Figure 3D, lane 1). RSK2 did not bind to GST, confirming that RSK2 binds the Tat component in the fusion protein (Figure 3D, lane 8). No binding was observed when only the N-terminal 35 amino acids of Tat were included in the reaction, indicating that these residues are not involved in RSK2 binding (Figure 3D, lane 2). Accordingly, binding was not reduced when RSK2 was incubated with a mutant Tat protein lacking amino acids 1-36 (Figure 3D, lane 3). However, deletion of amino acids 1-48 significantly reduced binding to RSK2, indicating that amino acids 37-48 in Tat are involved in RSK2 binding (Figure 3D, lane 4). Amino acids 37-48 correspond to the core region in Tat, which is necessary for Tat transactivation (reviewed in [50]). To confirm that this region is involved in RSK2 binding, we tested binding of RSK2 to three full-length GST-Tat fusion proteins with alanine-scanning mutations in the core region (Figure 3D, lanes 5, 6, 7). Binding to RSK2 was reduced to the greatest extent by mutation of amino acids 36-39, followed by mutations of amino acids 40-43 and amino acids 44-48. Thus, the critical interacting residues lie within amino acids 36-39 in Tat.
###end p 19
###begin p 20
###xml 340 349 340 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000151-g003">Figure 3E</xref>
###xml 658 667 658 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000151-g003">Figure 3E</xref>
Next, we mutated phenylalanine 38 (F38) to alanine within the full-length FLAG-tagged Tat expression vector used in coimmunoprecipitation experiments. After cotransfection of wild type Tat/FLAG or TatF38A/FLAG with RSK2/HA into Cos7 cells, coimmunoprecipitation of RSK2 was only detected for wild type, and not for the mutant, Tat protein (Figure 3E). The difference in detection of RSK2 in the presence of Tat is a variation in RSK2 expression rather than in RSK2 translocation, since the same pattern of RSK2 detection was observed in cytoplasmic extracts from the same experiment (not shown). The variation of Tat expression is unique to this experiment (Figure 3E).
###end p 20
###begin title 21
Transcriptional synergy with RSK2 is lost in TatF38A
###end title 21
###begin p 22
###xml 118 122 118 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Rice1">[51]</xref>
###xml 295 299 295 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Neuveut1">[52]</xref>
###xml 301 305 301 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Jeang1">[53]</xref>
###xml 459 468 459 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000151-g004">Figure 4A</xref>
###xml 804 813 804 813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000151-g004">Figure 4B</xref>
###xml 934 943 934 943 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000151-g004">Figure 4B</xref>
###xml 291 294 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 445 448 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 599 602 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
F38 is a highly conserved residue in Tat, and alanine substitution was shown to abrogate Tat transcriptional activity [51]. Others reported normal transactivation of a TatF38 mutant (TatF38L) in transfection assays, but impaired viral growth when the mutation was introduced into infectious HIV [52], [53]. We transfected wild type Tat or TatF38A into Jurkat 1G5 cells and found that the mutation abrogated Tat transactivation of the integrated HIV promoter (Figure 4A). To test whether the mutation affected synergy with RSK2, we cotransfected Tat- and RSK2-expressing constructs together with the HIV LTR luciferase reporter into CLS cells. While RSK2 synergized with wild type Tat, no synergy was observed with TatF38A, supporting the model that RSK2 suppports Tat transactivation via binding to F38 (Figure 4B). Again, kinase-deficient RSK2 had no effect, confirming that RSK2 catalytic activity is required for synergy with Tat (Figure 4B).
###end p 22
###begin title 23
Activation of the N-terminal RSK2 kinase activity by Tat
###end title 23
###begin p 24
###xml 140 148 140 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 472 481 472 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000151-g005">Figure 5A</xref>
To examine the Tat-interacting domain in RSK2, we performed binding studies using biotinylated synthetic Tat protein (amino acids 1-72) and in vitro synthesized radioactive RSK2. We also tested two RSK2 deletion mutants spanning amino acids 1-360 and 375-740, respectively. After pull-down with streptavidin-agarose, full-length RSK2 and RSK2 1-360 interacted in a dose-dependent manner with Tat, indicating that the Tat-interacting domain lies in the N-terminus of RSK2 (Figure 5A). No signal was detected when RSK2 was incubated with streptavidin-agarose alone, excluding unspecific binding in this assay.
###end p 24
###begin p 25
###xml 446 455 446 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000151-g005">Figure 5B</xref>
Amino acids 1-360 harbor the N-terminal kinase domain, which mediates substrate phosphorylation by RSK2. To determine if Tat binding affects the kinase activity of RSK2, we transfected Cos7 cells with Tat- or TatF38A-expressing constructs and performed standard S6 peptide phosphorylation assays after immunoprecipitation of endogenous RSK2. Expression of wild type, but not mutant Tat increased the kinase activity of endogenous RSK2 threefold (Figure 5B), as did epidermal growth factor (EGF), a natural stimulus of RSK2 kinase activity (not shown).
###end p 25
###begin p 26
###xml 211 215 211 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Dalby1">[54]</xref>
###xml 559 568 559 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000151-g005">Figure 5C</xref>
###xml 717 726 717 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000151-g005">Figure 5C</xref>
Activation of RSK2 by Tat was further examined by western blot analysis. After mitogenic stimulation, serine 227 (S227) in RSK2 is phosphorylated, an event that correlates with substrate phosphorylation by RSK2 [54]. We cotransfected RSK2/HA- and Tat/FLAG-expressing constructs in Cos7 cells and examined cell lysates with antibodies specific for phospho-S227 in RSK2. Phosphorylation in RSK2 was enhanced by wild type Tat, but not TatF38A, indicating that Tat binding to RSK2 is required for the increase in kinase activity and S227 phosphorylation of RSK2 (Figure 5C). Reprobing of the membrane with HA- and FLAG-specific antibodies showed similar levels of RSK2/HA and both Tat proteins throughout the experiment (Figure 5C).
###end p 26
###begin p 27
###xml 453 458 445 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c-fos</italic>
###xml 636 643 624 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 645 654 633 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000151-g005">Figure 5D</xref>
###xml 920 925 904 909 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c-fos</italic>
###xml 1014 1023 994 1003 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000151-g005">Figure 5D</xref>
###xml 41 44 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 209 212 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 252 255 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 420 423 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 501 504 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 628 631 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 809 812 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
To test whether Tat recruits RSK2 to the HIV promoter, we performed ChIP assays with alpha-phospho-S227 antibodies. Chromatin solutions were extracted from Jurkat T cells containing a single integrated latent HIV genome. Following TNF-alpha treatment, HIV transcription is activated in these cells and Tat is produced. The DNA immunoprecipitated along with phospho-S227 was analyzed by PCR with primers specific for the HIV promoter or for the cellular c-fos gene. After induction with TNF-alpha, the HIV LTR-specific sequence was enriched in the immunoprecipitated fraction, demonstrating that phospho-RSK2 is recruited to the HIV LTR in vivo (Figure 5D). TNF-alpha treatment alone did not activate S227 phosphorylation in the absence of Tat, suggesting that the recruitment or the activation of RSK2 at the HIV promoter occurred specifically in the presence of Tat (data not shown). No enrichment was observed for the c-fos-specific sequence or when alpha-phospho-S227 antibodies were omitted from the reaction (Figure 5D).
###end p 27
###begin title 28
###xml 15 18 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Suppression of HIV transcription by FMK, a novel inhibitor of RSK2
###end title 28
###begin p 29
###xml 209 213 205 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Cohen1">[55]</xref>
###xml 362 371 358 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000151-g006">Figure 6A</xref>
###xml 556 565 552 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000151-g006">Figure 6B</xref>
###xml 279 282 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Recently, a structural bioinformatics-based approach was used to design selective inhibitors of RSK1, 2, and 4, including the compound FMK, which at 1 or 10 microM inactivates RSK1 and RSK2 in mammalian cells [55]. Treatment of Jurkat 1G5 cells with FMK suppressed Tat-dependent HIV transcription in a dose-dependent manner after transfection of the Tat vector (Figure 6A). Importantly, FMK did not suppress the transcriptional activity of the Gal4-CDK9 fusion protein, confirming that the effects of RSK2 on Tat transactivation are not mediated by pTEFb (Figure 6B).
###end p 29
###begin p 30
###xml 115 120 115 120 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NL4-3</sub>
###xml 184 187 184 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nef</italic>
###xml 193 197 193 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Jordan2">[56]</xref>
###xml 259 262 259 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">env</italic>
###xml 717 733 705 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000151-g006">Figures 6C and D</xref>
###xml 32 35 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 71 74 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 486 489 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 618 621 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 825 828 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
To examine the effect of FMK on HIV infection, we generated infectious HIV particles using a molecular clone of HIVNL4-3 that contains the GFP open reading frame in place of the viral nef gene [56]. This clone also contains a frameshift mutation in the viral env gene, restricting analysis to a single infection cycle. Viral particles were pseudotyped with VSV-G. Jurkat T cells were incubated with viral supernatant, washed, and treated with FMK (10 microM) or DMSO alone. FMK reduced HIV gene expression two- to threefold, as measured by GFP expression, but had no effect on GFP expression in cells infected with an HIV-based lentiviral vector expressing GFP from the elongation factor 1alpha (EF-1alpha) promoter (Figures 6C and D). These data indicate that the RSK2 kinase activity regulates viral gene expression during HIV infection.
###end p 30
###begin title 31
Discussion
###end title 31
###begin p 32
###xml 332 335 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 366 369 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 403 411 <span type="species:ncbi:9606">patients</span>
###xml 975 978 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1025 1028 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
This study shows that RSK2 is a novel regulator of Tat transactivation, a conclusion supported by three independent observations. First, a dominant-negative form of RSK2, but not of other histone kinases, inhibited Tat transactivation. This effect was specific for Tat since no effect was observed on basal promoter activity of the HIV LTR or on the Tat-independent CMV promoter. Second, cells from CLS patients, which lack RSK2, exhibited a transcriptional defect. Ectopic expression of RSK2, but not of a catalytically inactive mutant, enhanced Tat transactivation in CLS cells, demonstrating that the kinase activity of RSK2 is important for Tat transactivation. In contrast, RSK2 overexpression in CLS cells slightly inhibited the transcriptional activity of the VP16 transactivator, demonstrating that RSK2 targets Tat specifically and that its overexpression does not induce general cell hyperactivation. Third, the RSK inhibitor FMK suppressed Tat transactivation and HIV gene expression. This effect was specific for HIV transcription, since no effect was observed on the infection with control viral vectors, in which GFP expression was driven by the cellular EF-1alpha promoter.
###end p 32
###begin p 33
###xml 255 258 255 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Wei1">[5]</xref>
###xml 260 264 260 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Mujtaba1">[22]</xref>
###xml 266 270 266 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Dorr1">[23]</xref>
A Tat mutant (F38A) that does not bind RSK2 exhibited a transcriptional defect that cannot be attributed exclusively to RSK2. F38 lies in the core domain of Tat, which is involved in binding of other transcriptional cofactors, including cyclinT1 and PCAF [5], [22], [23]. Interestingly, kinase-deficient RSK2 and the RSK inhibitor FMK had no effect on the transcriptional activity of CDK9, the binding partner of cyclinT1 and the kinase component of pTEFb. This finding excludes the possibility that RSK2 regulates Tat transactivation through pTEFb.
###end p 33
###begin p 34
###xml 375 379 371 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Smith1">[57]</xref>
###xml 381 385 377 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-PoteetSmith1">[58]</xref>
###xml 525 529 521 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Frodin1">[59]</xref>
The observation that Tat activates the kinase activity of RSK2 is unexpected and shows an important novel function of Tat. The enzymatic activity of RSK2 is regulated by sequential phosphorylation events. Phosphorylation by ERK1/2 displaces an inhibitory alpha-helix from the substrate-binding region of the C-terminal kinase domain of RSK2 and activates its kinase activity [57], [58]. This leads to autophosphorylation of serine 386 (S386) in the linker region between the kinase domains, which recruits and activates PDK1 [59]. PDK1 phosphorylates S227 in the N-terminal kinase domain, the final step in the phosphorylation cascade, and induces substrate phosphorylation.
###end p 34
###begin p 35
###xml 268 272 268 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-delaFuente1">[60]</xref>
###xml 661 665 661 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Yang2">[61]</xref>
###xml 967 971 967 971 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Cohen1">[55]</xref>
###xml 1189 1193 1182 1186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Ge1">[62]</xref>
###xml 1515 1519 1504 1508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-PoteetSmith1">[58]</xref>
###xml 436 439 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 905 915 <span type="species:ncbi:111938">gatekeeper</span>
We have shown that this final step is activated by Tat. It is not clear whether Tat binding leads to immediate phosphorylation of S227 or involves the classical MAPK-induced activation cascade. Interestingly, ERK1 expression might be decreased in cells expressing Tat [60]. Direct activation of RSK2 by Tat, independently of upstream activation signals, could therefore compensate for a decrease in ERK1 expression and signaling during HIV infection. We and others observed that U0126, an inhibitor of MAPK/ERK kinase (MEK), the kinase upstream of ERK, had no effect on Tat transactivation, supporting the notion that Tat targets RSK2 directly (data not shown; [61]). Moreover, FMK, a direct inhibitor of RSK2 kinase activity, suppressed Tat transactivation in a dose-dependent manner. FMK selectively inhibits the C-terminal kinase domain and targets a reactive cysteine that, together with a threonine "gatekeeper," controls access of FMK to the ATP binding pocket [55]. A recent study found MAP kinase p38alpha activated through direct binding by the adaptor protein transforming growth factor-beta-activated protein kinase 1-binding protein 1 (TAB1) in the absence of upstream signals [62]. It was proposed that TAB1 binding induced a conformational change in p38alpha, which activated its kinase activity and enhanced the level of kinase autophosphorylation. One possibility is that Tat through binding to the N-terminal kinase domain, which does not exhibit substantial intrinsic autophosphorylation activity [58], alters the structural conformation of RSK2 and stimulates the autophosphorylation activity of the C-terminal kinase domain, leading to phosphorylation of S386 and subsequently S227. In addition, by direct binding to the N-terminal kinase domain, Tat could activate S227 phosphorylation through an unknown mechanism.
###end p 35
###begin p 36
###xml 169 176 169 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 321 325 321 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Lusic1">[14]</xref>
###xml 327 331 327 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Mujtaba1">[22]</xref>
###xml 333 337 333 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Dorr1">[23]</xref>
###xml 339 343 339 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Bres1">[63]</xref>
###xml 156 159 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 551 554 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 926 929 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Our experiments show that phosphorylation of histone H3 is enhanced in Tat-expressing T cells. In addition, we show that activated RSK2 is recruited to the HIV promoter in vivo, where it can target histones. We and others have previously shown that Tat also recruits the HAT activity of PCAF via its acetylated lysine 50 [14], [22], [23], [63]. Since at some promoters acetylation of lysine 14 in histone H3 - mediated by PCAF - is enhanced when serine 10 is phosphorylated, the two functions of Tat can be expected to synergize in the stimulation of HIV transcription. However, in our experiments the positive effect of RSK2 on Tat transactivation was observed on integrated as well as nonintegrated LTR promoter templates, which may indicate that RSK2 targets additional substrates besides histones. Future experiments will address the role of RSK2 in the phosphorylation of histone H3 or other known RSK2 substrates at the HIV promoter, including CBP, CREB, c-fos and ATF4.
###end p 36
###begin title 37
Material and Methods
###end title 37
###begin title 38
Cells and plasmids
###end title 38
###begin p 39
Cos7, HeLa, 293, and Jurkat cells (American Type Culture Collection), Jurkat 1G5 cells (AIDS Research and Reference Reagent Program), and CLS fibroblasts (Coriell Institute for Medical Research, Camden, NJ) were cultured under standard cell culture conditions. Jurkat 1G5 cells were transiently transfected with the DEAE-dextrane technique, and luciferase activity was measured 20 h later (Promega).
###end p 39
###begin p 40
###xml 78 82 78 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Jordan2">[56]</xref>
###xml 84 88 84 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Kaehlcke1">[64]</xref>
###xml 259 263 259 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Xing1">[45]</xref>
###xml 409 413 405 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-OMahony1">[65]</xref>
###xml 580 584 576 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Frodin1">[59]</xref>
###xml 586 590 582 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Frodin2">[66]</xref>
###xml 712 720 708 716 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1009 1013 1005 1009 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Chen2">[67]</xref>
###xml 1108 1112 1104 1108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Puigserver1">[68]</xref>
###xml 1425 1429 1421 1425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Fujinaga1">[69]</xref>
###xml 1495 1499 1491 1495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Ott1">[25]</xref>
###xml 1533 1537 1529 1533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Emiliani1">[70]</xref>
###xml 1679 1682 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 1844 1847 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
Jurkat cells were stably infected with lentiviral vectors expressing Tat/FLAG [56], [64]. Constructs encoding N-terminal HA-tagged wild type and dominant-negative RSK2 (K100A) were provided by M. Greenberg (Harvard Medical School, Boston, Massachusetts, USA) [45], dominant-negative IKKalpha (K44M) by W. Greene and A. O'Mahony (Gladstone Institute of Virology and Immunology, San Francisco, California, USA) [65], dominant-negative MSK1 (R102A) and HA-tagged RSK2 and deletion mutants by M. Frodin (Department of Clinical Biochemistry, Glostrup Hospital, 2600 Glostrup, Denmark) [59], [66]. NotI/XhoI fragments from these RSK2 vectors were blunted and subcloned into the EcoRV site of pcDNA3.1 (Invitrogen) for in vitro transcription/translation (Promega). GST-Tat 1-86 and 1-48 were obtained from the AIDS Research and Reference Reagent Program. All other GST-Tat deletion constructs were a gift from Q. Zhou and D. Chen (Department of Molecular and Cell Biology, University of California, California, USA) [67]. The 5xUAS construct, in which 5 x Gal4 binding sites were cloned upstream of the TK promoter [68], was provided by B. Spiegelman (Dana-Farber Cancer Institute and Department of Cell Biology, Harvard Medical School, Boston, Massachusetts, USA) and the Gal4-CDK9 construct by M. Peterlin (Department of Medicine, Rosalind Russell Medical Research Center, University of California, San Francisco, California,USA) [69]. Full-length Tat (101 amino acids) bearing a C-terminal FLAG tag [25] and the LTR luciferase construct [70] have been described. The Tat-FLAG construct served as template for site-directed mutagenesis (Stratagene) to generate the F38A mutation. The CMV luciferase construct was generated by cloning the luciferase gene as a HindIII/BamHI fragment obtained from pGL2 Basic (Promega) into pcDNA3.1 (Invitrogen). The CMV-GFP construct was purchased from Clontech.
###end p 40
###begin title 41
ChIP Assays
###end title 41
###begin p 42
###xml 320 324 316 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Morshead1">[71]</xref>
###xml 889 893 857 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Kaehlcke1">[64]</xref>
###xml 147 150 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 412 418 <span type="species:ncbi:9986">rabbit</span>
###xml 488 494 <span type="species:ncbi:9986">rabbit</span>
Jurkat cells, 24 h after transduction with lentiviral vectors encoding either Tat or GFP and Jurkat clone A2 containing a single integrated latent HIV minigenome induced with TNF-alpha (10 ng/ml; Biosource) were fixed with 1% formaldehyde, partially digested with micrococcal nuclease (Roche) and sonicated as described [71]. Precleared chromatin solutions were incubated overnight at 4degreesC with 1 microg of rabbit alpha-phospho-histone H3 (S10; Upstate Biotechnology) or 5 microg of rabbit alpha-phospho-S227 (Santa Cruz Biotechnology). Immune complexes were collected with protein A-sepharose preblocked with sonicated salmon sperm DNA (Upstate Biotechnology). Formaldehyde cross-links were reverted by incubating the samples at 65degreesC overnight in the presence of 200 mM NaCl. One-tenth of the immunoprecipitated DNA was used in PCR reactions using primers previously described [64].
###end p 42
###begin title 43
Viral infection experiments
###end title 43
###begin p 44
###xml 137 141 137 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Kaehlcke1">[64]</xref>
###xml 291 294 291 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nef</italic>
###xml 294 298 294 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Jordan2">[56]</xref>
###xml 495 499 487 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Naldini1">[72]</xref>
###xml 237 240 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 539 565 <span type="species:ncbi:11276">vesicular stomatitis virus</span>
Jurkat T cells infected with lentiviral vectors expressing Tat/FLAG or GFP used in coimmunoprecipitation experiments have been described [64]. For studies with the RSK2 inhibitor FMK, Jurkat cells were infected with a molecular clone of HIV containing the GFP open reading frame in place of nef[56]. FMK is a pyrrolopyrimidine that contains a fluoromethylketone. Minimal lentiviral vectors driving GFP expression from a heterologous promoter (EF-1alpha) served as a control (pHR'-EF-1alpha/GFP) [72]. Viral particles were pseudotyped with vesicular stomatitis virus glycoprotein (VSV-G). All vectors and protocols to generate lentiviral particles were provided by D. Trono (EPFL SV-DO, Lausanne, Switzerland). Jurkat T cells were incubated overnight with lentiviral particles at a theoretical multiplicity of infection (m.o.i.) of 0.5 in 24-well plates. Cells were repeatedly washed and resuspended in fresh medium containing FMK (1 or 10 microM) or DMSO alone. Viral infection was monitored 36 h later by flow cytometric analysis using a Calibur FACScan (Beckton Dickinson).
###end p 44
###begin title 45
Nuclear microinjections and transfections of CLS cells
###end title 45
###begin p 46
###xml 385 389 377 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Dorr1">[23]</xref>
###xml 391 395 383 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Kaehlcke1">[64]</xref>
###xml 439 442 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 491 494 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
Subconfluent CLS fibroblasts were grown on Cellocate coverslips (Eppendorf) and were microinjected at room temperature with an automated injection system (Carl Zeiss) or a micromanipulator/transjector (Eppendorf). The medium was buffered during the microinjection by adding 20 mM HEPES buffer. Samples were prepared as a 20 microl injection mix containing synthetic Tat (30 ng/microl) [23], [64] and the LTR luciferase (100 ng/microl) and CMV-GFP (50 ng/microl) constructs together with the CMV-RSK2 expression construct or the empty vector (each 200 ng/microl). Live cells were examined on a Zeiss Axiovert or a Nikon Eclipse TE300 microscope to determine the number of GFP-positive cells. Four hours after injection, cells were washed in cold PBS and processed for luciferase assays (Promega).
###end p 46
###begin p 47
###xml 168 171 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
For transfections, subconfluent CLS fibroblasts in six-well plates were transfected using Lipofectamine reagent (Invitrogen) and Tat-expressing plasmid (0.3 and 3 ng), HIV LTR luciferase reporter (200 ng) and RSK2-expressing constructs or empty vector (each 200 ng). Cells were harvested twenty-four hours after transfections and equal amounts of cellular extract (as measured by protein content) processed for luciferase assays (Promega).
###end p 47
###begin title 48
Coimmunoprecipitation and western blot analysis
###end title 48
###begin p 49
###xml 16 17 16 17 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 234 238 230 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Merienne1">[43]</xref>
Cos7 cells (3x105) were transfected with Tat- and RSK2-expressing plasmids (6 microg) with Lipofectamine reagent (Invitrogen). Twenty-four hours after transfection, nuclear extracts were prepared in hypotonic buffer (HB) as described [43]. Equal amounts of nuclear extracts were precleared with protein A- or G-sepharose (Amersham Pharmacia Biotech) that had been blocked with 50 mg/ml BSA in HB for 1 h at 4degreesC. Precleared nuclear extracts were immunoprecipitated with alpha-FLAG (Sigma), alpha-HA (Roche), or alpha-RSK2 (Santa Cruz Biotechnology) antibodies and protein A- or G-sepharose overnight at 4degreesC in HB supplemented with 120 mM NaCl. Pellets were washed five times in HB supplemented with 120 mM NaCl, resuspended in Laemmli buffer, and analyzed by western blot with alpha-FLAG, alpha-HA or alpha-RSK2 antibodies.
###end p 49
###begin p 50
###xml 203 207 203 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Kaehlcke1">[64]</xref>
###xml 323 327 323 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Frodin1">[59]</xref>
###xml 195 198 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Tat and endogenous RSK2 were coimmunoprecipitated from cellular extracts isolated from Jurkat cells or Jurkat cells infected with a lentiviral vector expressing Tat/FLAG under the control of the HIV LTR [64]. Western blot analysis with phospho-S227-specific antibodies (Santa Cruz Biotechnology) was performed as described [59].
###end p 50
###begin title 51
Kinase assays
###end title 51
###begin p 52
###xml 273 277 269 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Merienne1">[43]</xref>
Nuclear extracts from Cos7 cells transfected with Tat/FLAG, Tat F38A/FLAG, or vector alone were immunoprecipitated with alpha-RSK2 antibodies as described above. Immunoprecipitates were washed three times in HB supplemented with 120 mM NaCl and once in kinase assay buffer [43]. Kinase assays were performed with a standard S6 kinase protocol (Upstate Biotechnology).
###end p 52
###begin title 53
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
In vitro binding assays
###end title 53
###begin p 54
###xml 73 81 73 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 139 141 135 137 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 282 286 278 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Dorr1">[23]</xref>
###xml 288 292 284 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Kaehlcke1">[64]</xref>
Constructs encoding wild type RSK2 or deletion mutants were subjected to in vitro transcription/translation in the presence of 20 microCi [35S]-methionine (Amersham Pharmacia Biotech) using the TNT T7-coupled reticulocyte lysate system (Promega). Biotinylated synthetic Tat protein [23], [64], immobilized to streptavidin-sepharose, was incubated with 0.5 or 1.5 microl of reticulocyte lysate containing radioactive RSK2 proteins in HB buffer supplemented with 120 mM NaCl described above. Binding reactions were incubated for 10 min at 30degreesC, washed three times in binding buffer containing 1 M KCl, and analyzed by SDS-PAGE. The gel was fixed, amplified (Amersham Pharmacia Biotech), and exposed to BioMax MR film (Kodak).
###end p 54
###begin p 55
###xml 57 73 57 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Escherichia coli</italic>
###xml 127 130 127 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000151-Herrmann1">[6]</xref>
###xml 57 73 <span type="species:ncbi:562">Escherichia coli</span>
GST fusion proteins were expressed in the BL21 strain of Escherichia coli and purified with glutathione-sepharose as described [6]. Bound proteins were eluted with 25 mM glutathione (Sigma), dialyzed (50 mM Tris, pH 8.0, 20 mM NaCl, 0.5% NP-40, 5 mM DTT, 50 microg/ml AEBSF, 15% glycerol), and protein concentrations were measured with the RC DC protein assay (Bio-Rad) and verified after SDS-PAGE by Coomassie staining or western blot analysis.
###end p 55
###begin p 56
###xml 4 12 4 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 513 518 <span type="species:ncbi:9606">human</span>
For in vitro binding studies, equal amounts of GST proteins (1 microg/microl) were immobilized to glutathione-sepharose beads that had been blocked with 50 mg/ml BSA in binding buffer (20 mM Hepes, pH 7.9, 1% Triton, 0.5% NP-40, 200 mM KCl, 0.1% BSA, 2 mM DTT, protease inhibitor cocktail). After three washes in EBC/DTT/SDS (50 mM Tris, pH 8.0, 20 mM NaCl, 0.5% NP-40, 5 mM DTT, 50 microg/ml AEBSF, 0.075% SDS, protease inhibitor cocktail) and one wash in binding buffer, the beads were incubated with 200 ng of human recombinant RSK2 (Upstate Biotechnology). Bead-coupled proteins were washed three times in binding buffer containing 1 M KCl and boiled in Laemmli buffer, and supernatants were analyzed by western blot analysis with alpha-RSK2 antibodies (Santa Cruz Biotechnology).
###end p 56
###begin p 57
We thank J. Carroll, J. Hull, and C. Goodfellow for graphics, S. Ordway and G. Howard for editorial assistance and Amanda Bradford for administrative assistance. We thank D. Chen, Q. Zhou, M. Frodin, P. Sassone-Corsi, K. Merienne, B. Spiegelman, M. Peterlin, A. O'Mahony, W. Greene, M. Greenberg, and S. Pagans for sharing their reagents and protocols, D. Trono for providing lentiviral vectors, M. Schnoelzer, W. Greene, M. Weitzman, and E. Verdin for helpful discussions and M. Hetzer for continuous support. This article is dedicated to H. zur Hausen on the occasion of his retirement as head of the Deutsches Krebsforschungszentrum (DKFZ) with gratitude and appreciation for 20 years of leadership.
###end p 57
###begin title 58
References
###end title 58
###begin article-title 59
###xml 69 74 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product.
###end article-title 59
###begin article-title 60
###xml 34 37 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Hide, shield and strike back: how HIV-infected cells avoid immune eradication.
###end article-title 60
###begin article-title 61
###xml 12 17 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 37 42 <span type="species:ncbi:9606">human</span>
The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation.
###end article-title 61
###begin article-title 62
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 auxiliary proteins: making connections in a dying cell.
###end article-title 62
###begin article-title 63
###xml 62 67 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA.
###end article-title 63
###begin article-title 64
###xml 28 56 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Specific interaction of the human immunodeficiency virus Tat proteins with a cellular protein kinase.
###end article-title 64
###begin article-title 65
###xml 55 60 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro.
###end article-title 65
###begin article-title 66
The language of covalent histone modifications.
###end article-title 66
###begin article-title 67
RNA polymerase II elongation through chromatin.
###end article-title 67
###begin article-title 68
Tails of intrigue: phosphorylation of RNA polymerase II mediates histone methylation.
###end article-title 68
###begin article-title 69
###xml 59 64 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation.
###end article-title 69
###begin article-title 70
###xml 66 101 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Chromatin disruption and histone acetylation in regulation of the human immunodeficiency virus type 1 long terminal repeat by thyroid hormone receptor.
###end article-title 70
###begin article-title 71
###xml 109 144 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 146 151 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 160 165 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 184 189 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator Tat.
###end article-title 71
###begin article-title 72
###xml 14 19 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Regulation of HIV-1 gene expression by histone acetylation and factor recruitment at the LTR promoter.
###end article-title 72
###begin article-title 73
###xml 105 140 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Coordination of transcription factor phosphorylation and histone methylation by the P-TEFb kinase during human immunodeficiency virus type 1 transcription.
###end article-title 73
###begin article-title 74
###xml 107 112 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Identification of a cellular protein that specifically interacts with the essential cysteine region of the HIV-1 Tat transactivator.
###end article-title 74
###begin article-title 75
###xml 106 111 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Activation of integrated provirus requires histone acetyltransferase. p300 and P/CAF are coactivators for HIV-1 Tat.
###end article-title 75
###begin article-title 76
###xml 15 50 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Interaction of human immunodeficiency virus type 1 Tat with the transcriptional coactivators p300 and CREB binding protein.
###end article-title 76
###begin article-title 77
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 tat transactivator recruits p300 and CREB-binding protein histone acetyltransferases to the viral promoter.
###end article-title 77
###begin article-title 78
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 tat binds TAFII250 and represses TAFII250-dependent transcription of major histocompatibility class I genes.
###end article-title 78
###begin article-title 79
###xml 72 75 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The histone acetyltransferase, hGCN5, interacts with and acetylates the HIV transactivator, Tat.
###end article-title 79
###begin article-title 80
###xml 38 43 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Structural basis of lysine-acetylated HIV-1 Tat recognition by PCAF bromodomain.
###end article-title 80
###begin article-title 81
Transcriptional synergy between Tat and PCAF is dependent on the binding of acetylated Tat to the PCAF bromodomain.
###end article-title 81
###begin article-title 82
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 tat transcriptional activity is regulated by acetylation.
###end article-title 82
###begin article-title 83
###xml 19 24 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Acetylation of the HIV-1 Tat protein by p300 is important for its transcriptional activity.
###end article-title 83
###begin article-title 84
###xml 15 20 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 75 80 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Acetylation of HIV-1 Tat by CBP/P300 increases transcription of integrated HIV-1 genome and enhances binding to core histones.
###end article-title 84
###begin article-title 85
Rapid histone H3 phosphorylation in response to growth factors, phorbol esters, okadaic acid, and protein synthesis inhibitors.
###end article-title 85
###begin article-title 86
Phosphorylation of serine 10 in histone H3 is functionally linked in vitro and in vivo to Gcn5-mediated acetylation at lysine 14.
###end article-title 86
###begin article-title 87
Synergistic coupling of histone H3 phosphorylation and acetylation in response to epidermal growth factor stimulation.
###end article-title 87
###begin article-title 88
Independent dynamic regulation of histone phosphorylation and acetylation during immediate-early gene induction.
###end article-title 88
###begin article-title 89
MSK2 and MSK1 mediate the mitogen- and stress-induced phosphorylation of histone H3 and HMG-14.
###end article-title 89
###begin article-title 90
Requirement of Rsk-2 for epidermal growth factor-activated phosphorylation of histone H3.
###end article-title 90
###begin article-title 91
The nucleosomal response associated with immediate-early gene induction is mediated via alternative MAP kinase cascades: MSK1 as a potential histone H3/HMG-14 kinase.
###end article-title 91
###begin article-title 92
A nucleosomal function for IkappaB kinase-alpha in NF-kappaB-dependent gene expression.
###end article-title 92
###begin article-title 93
Histone H3 phosphorylation by IKK-alpha is critical for cytokine-induced gene expression.
###end article-title 93
###begin article-title 94
Evidence for two catalytically active kinase domains in pp90rsk.
###end article-title 94
###begin article-title 95
Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction.
###end article-title 95
###begin article-title 96
The Coffin-Lowry syndrome.
###end article-title 96
###begin article-title 97
Mutations in the kinase Rsk-2 associated with Coffin-Lowry syndrome.
###end article-title 97
###begin article-title 98
###xml 51 59 <span type="species:ncbi:9606">patients</span>
Mutation analysis of the RSK2 gene in Coffin-Lowry patients: extensive allelic heterogeneity and a high rate of de novo mutations.
###end article-title 98
###begin article-title 99
Coffin-Lowry syndrome: clinical and molecular features.
###end article-title 99
###begin article-title 100
MSK1 and MSK2 mediate mitogen- and stress-induced phosphorylation of histone H3: a controversy resolved.
###end article-title 100
###begin article-title 101
Mitogen-regulated RSK2-CBP interaction controls their kinase and acetylase activities.
###end article-title 101
###begin article-title 102
The signal-dependent coactivator CBP is a nuclear target for pp90RSK.
###end article-title 102
###begin article-title 103
Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase.
###end article-title 103
###begin article-title 104
Transcription factor phosphorylation by pp90(rsk2). Identification of Fos kinase and NGFI-B kinase I as pp90(rsk2).
###end article-title 104
###begin article-title 105
ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology; implication for Coffin-Lowry Syndrome.
###end article-title 105
###begin article-title 106
###xml 20 48 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Trans-activation of human immunodeficiency virus gene expression is mediated by nuclear events.
###end article-title 106
###begin article-title 107
Nuclear localization and regulation of erk- and rsk-encoded protein kinases.
###end article-title 107
###begin article-title 108
###xml 48 53 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Control of RNA initiation and elongation at the HIV-1 promoter.
###end article-title 108
###begin article-title 109
###xml 65 100 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Mutational analysis of the conserved cysteine-rich region of the human immunodeficiency virus type 1 Tat protein.
###end article-title 109
###begin article-title 110
###xml 12 47 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Recombinant human immunodeficiency virus type 1 genomes with tat unconstrained by overlapping reading frames reveal residues in Tat important for replication in tissue culture.
###end article-title 110
###begin article-title 111
###xml 31 36 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Multifaceted activities of the HIV-1 transactivator of transcription, Tat.
###end article-title 111
###begin article-title 112
Identification of regulatory phosphorylation sites in mitogen-activated protein kinase (MAPK)-activated protein kinase-1a/p90rsk that are inducible by MAPK.
###end article-title 112
###begin article-title 113
Structural bioinformatics-based design of selective, irreversible kinase inhibitors.
###end article-title 113
###begin article-title 114
###xml 0 3 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
HIV reproducibly establishes a latent infection after acute infection of T cells in vitro.
###end article-title 114
###begin article-title 115
Identification of an extracellular signal-regulated kinase (ERK) docking site in ribosomal S6 kinase, a sequence critical for activation by ERK in vivo.
###end article-title 115
###begin article-title 116
Generation of constitutively active p90 ribosomal S6 kinase in vivo. Implications for the mitogen-activated protein kinase-activated protein kinase family.
###end article-title 116
###begin article-title 117
A phosphoserine/threonine-binding pocket in AGC kinases and PDK1 mediates activation by hydrophobic motif phosphorylation.
###end article-title 117
###begin article-title 118
###xml 27 32 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Gene expression profile of HIV-1 Tat expressing cells: a close interplay between proliferative and differentiation signals.
###end article-title 118
###begin article-title 119
###xml 14 49 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Regulation of human immunodeficiency virus type 1 infectivity by the ERK mitogen-activated protein kinase signaling pathway.
###end article-title 119
###begin article-title 120
MAPKK-independent activation of p38alpha mediated by TAB1-dependent autophosphorylation of p38alpha.
###end article-title 120
###begin article-title 121
Differential acetylation of Tat coordinates its interaction with the co-activators cyclin T1 and PCAF.
###end article-title 121
###begin article-title 122
###xml 58 61 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Acetylation of Tat defines a cyclinT1-independent step in HIV transactivation.
###end article-title 122
###begin article-title 123
Activation of the heterodimeric IkappaB kinase alpha (IKKalpha)-IKKbeta complex is directional: IKKalpha regulates IKKbeta under both basal and stimulated conditions.
###end article-title 123
###begin article-title 124
A phosphoserine-regulated docking site in the protein kinase RSK2 that recruits and activates PDK1.
###end article-title 124
###begin article-title 125
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Tat targets microtubules to induce apoptosis, a process promoted by the pro-apoptotic Bcl-2 relative Bim.
###end article-title 125
###begin article-title 126
Activation of PPARgamma coactivator-1 through transcription factor docking.
###end article-title 126
###begin article-title 127
###xml 21 26 <span type="species:ncbi:9606">human</span>
###xml 151 156 <span type="species:ncbi:10090">mouse</span>
Interactions between human cyclin T, Tat, and the transactivation response element (TAR) are disrupted by a cysteine to tyrosine substitution found in mouse cyclin T.
###end article-title 127
###begin article-title 128
###xml 24 29 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
A point mutation in the HIV-1 Tat responsive element is associated with postintegration latency.
###end article-title 128
###begin article-title 129
Antigen receptor loci poised for V(D)J rearrangement are broadly associated with BRG1 and flanked by peaks of histone H3 dimethylated at lysine 4.
###end article-title 129
###begin article-title 130
In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector.
###end article-title 130
###begin title 131
Figures and Tables
###end title 131
###begin title 132
Role of histone kinases in Tat transactivation.
###end title 132
###begin p 133
###xml 86 89 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 281 284 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 373 376 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 650 653 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
(A) Chromatin immunoprecipitation analysis of Jurkat T cells containing an integrated HIV promoter in the absence or presence of Tat. Immunoprecipitations were performed with alpha-phospho-histone H3 antibodies (serine 10) followed by radioactive PCR with primers specific for the HIV LTR, the c-fos, or the beta-globin genes. (B) Jurkat 1G5 cells containing an integrated HIV LTR luciferase construct were transiently transfected with Tat/FLAG (25 ng) and kinase-deficient (KD) kinase expression vectors (200 ng). (C) Western blot analysis of cellular lysates from 293 cells cotransfected with the indicated expression plasmids. (D) Transfection of CMV luciferase (25 ng) with the KD RSK2 expression plasmid (200 ng) in Jurkat cells. (E) Transfection of 5xUAS luciferase and Gal4-CDK9 (20 ng) with the KD RSK2 expression plasmid (200 ng) in Jurkat cells. Values are means+/-SEM of three experiments.
###end p 133
###begin title 134
Superinduction of Tat activity in CLS fibroblasts.
###end title 134
###begin p 135
###xml 69 76 <span type="species:ncbi:9606">patient</span>
###xml 98 103 <span type="species:ncbi:9606">human</span>
###xml 206 209 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 237 240 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 519 522 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
(A) Western blot analysis of cellular extracts of fibroblasts from a patient with CLS and control human fibroblasts. (B) Nuclear microinjection of CLS fibroblasts with synthetic Tat (amino acids 1-72), the HIV LTR luciferase reporter, a CMV-GFP expression plasmid, and either the empty vector, an RSK2 expression construct, or a plasmid expressing kinase-deficient RSK2. Values are means+/-SEM of five experiments. (C) Coinjection of the 5xUAS luciferase reporter, a plasmid expressing the Gal4-VP16 transactivator and CMV-GFP with either the RSK2-expressing plasmid or the vector alone. Values are means+/-SEM of three experiments.
###end p 135
###begin title 136
###xml 28 35 28 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 40 49 40 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro.</italic>
Interaction of Tat and RSK2 in vivo and in vitro.
###end title 136
###begin p 137
###xml 614 622 606 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 479 482 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 536 539 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
(A) Coimmunoprecipitation of RSK2 with Tat in nuclear extracts from Cos7 cells cotransfected with RSK2/HA and Tat/FLAG. One representative experiment of five is shown. (B) Coimmunoprecipitation of Tat with endogenous RSK2 in nuclear extracts from Cos7 cells transfected with Tat/FLAG. Immunoprecipitations were performed three times with alpha-RSK2 or alpha-CD71 antibodies as a control. (C) Coimmunoprecipitation of Tat with endogenous RSK2 in Jurkat T cells transduced with an HIV-based lentiviral vector expressing Tat/FLAG from the HIV LTR and in uninfected Jurkat T cells. One experiment of two is shown. (D) In vitro binding of GST-Tat (amino acids 1-86) or Tat mutants to full-length recombinant RSK2. Western blotting of RSK2 before (Input) and after GST binding is shown. One representative experiment of three is shown. (E) Coimmunoprecipitation of RSK2 with wild type Tat, but not with mutant TatF38A, in nuclear extracts of cotransfected Cos7 cells. Results were confirmed in three independent experiments.
###end p 137
###begin title 138
Transcriptional activity of TatF38A.
###end title 138
###begin p 139
###xml 197 200 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
(A) Transfection of indicated amounts of Tat- or TatF38A-expressing constructs in Jurkat 1G5 cells using the DEAE-dextran method. (B) Cotransfection of indicated amounts of Tat or TatF38A with the HIV LTR luciferase (200 ng) and wild type or kinase-deficient RSK2 (200 ng) in CLS cells. Values are means+/-SEM of five experiments for wild type and three experiments for mutant Tat.
###end p 139
###begin title 140
Activation of RSK2 by Tat.
###end title 140
###begin p 141
###xml 35 43 35 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 193 201 193 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 799 802 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 856 859 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1077 1080 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
(A) Autoradiography of radioactive in vitro synthesized RSK2 proteins before (Input) and after binding to biotinylated synthetic Tat (amino acids 1-72) or to beads alone. Increasing amounts of in vitro translated RSK2 were included in the binding reaction. (B) Kinase assay of endogenous RSK2 immunoprecipitated from Cos7 cells transfected with wild type Tat/FLAG, TatF38A/FLAG, or empty vector. Values are means+/-SEM of four experiments. (C) Western blotting of nuclear extracts isolated from Cos7 cells cotransfected with RSK2/HA and Tat/FLAG or with RSK2/HA and Tat F38A/FLAG constructs. Densitometric quantification of the phospho-S227-specific bands was performed using the NIH Image software. (D) Chromatin immunoprecipitation analysis of the Jurkat T cell line A2, latently infected with an HIV-based lentiviral vector expressing Tat/FLAG from the HIV LTR after treatment with TNF-alpha. At indicated time points, cells were harvested and immunoprecipitations were performed in duplicate with alpha-phospho-S227 antibodies followed by PCR with primers specific for the HIV LTR or the c-fos gene.
###end p 141
###begin title 142
###xml 15 18 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Suppression of HIV transcription by FMK, a small-molecule inhibitor of RSK2.
###end title 142
###begin p 143
###xml 498 503 494 499 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NL4-3</sub>
###xml 564 567 560 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nef</italic>
###xml 799 800 789 790 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 73 76 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 584 587 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 875 878 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 886 889 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
(A) Transient transfection of Jurkat 1G5 cells, containing an integrated HIV LTR luciferase construct, with Tat/FLAG (20 and 200 ng). Transfected cells were treated with indicated amounts of FMK or DMSO for 18 h. Values are mean+/-SEM of four experiments. (B) Cotransfection of Jurkat T cells with 5xUAS luciferase and Gal4-CDK9 (20 ng) and subsequent treatment with FMK at indicated concentrations. Values are means+/-SEM of four experiments. (C) GFP expression in Jurkat T cells infected with HIVNL4-3 containing the GFP open reading frame in place of the viral nef gene or with an HIV-based lentiviral vector expressing GFP from the heterologous EF-1alpha promoter. After overnight infection, cells were treated with FMK or DMSO for 36 h. Values are means+/-SEM of three experiments. *p = 0.002 (t test). (D) GFP expression in one representative experiment performed with HIV GFP or HIV (EF-1alpha) GFP virus.
###end p 143
###begin p 144
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 144
###begin p 145
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by grants from the Searle Scholars Foundation and the NIH to J.T. and grants from the Helmholtz-Gemeinschaft deutscher Forschungszentren and Public Health Service grants (NIAID AI057179-02 and NIAID AI065248-02) to M.O. The sponsors had no role in the study design, collection, analysis, and interpretation of data or the writing and submission of the manuscript.
###end p 145

